However, it’s an imperfect biomarker since in some tumors, such as renal cell carcinoma and first-line bladder cancer [37], there appears to be no correlation between PD-L1 expression and the likelihood of clinical response. The gene discussed is CD274; the disease is urinary bladder cancer.